EA200602196A1 - Производные пиразола, композиции, содержащие эти соединения, и способы применения - Google Patents

Производные пиразола, композиции, содержащие эти соединения, и способы применения

Info

Publication number
EA200602196A1
EA200602196A1 EA200602196A EA200602196A EA200602196A1 EA 200602196 A1 EA200602196 A1 EA 200602196A1 EA 200602196 A EA200602196 A EA 200602196A EA 200602196 A EA200602196 A EA 200602196A EA 200602196 A1 EA200602196 A1 EA 200602196A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
pyrazol
derivatives
connections
application
Prior art date
Application number
EA200602196A
Other languages
English (en)
Other versions
EA012431B1 (ru
Inventor
Эмма Р. Парми
Юйшэн Сюн
Цзянь Го
Жуй Лян
Линда Броканьер
Original Assignee
Мерк Энд Ко., Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мерк Энд Ко., Инк. filed Critical Мерк Энд Ко., Инк.
Publication of EA200602196A1 publication Critical patent/EA200602196A1/ru
Publication of EA012431B1 publication Critical patent/EA012431B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Раскрыты пиразолы, содержащие присоединенную нафтильную группу. Данные соединения полезны для лечения диабета 2 типа и родственных состояний. Также раскрыты фармацевтические композиции и способы лечения.
EA200602196A 2004-06-04 2005-05-31 Производные пиразола, фармацевтические композиции и их применение EA012431B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57711604P 2004-06-04 2004-06-04
PCT/US2005/018828 WO2005121097A2 (en) 2004-06-04 2005-05-31 Pyrazole derivatives, compositions containing such compounds and methods of use

Publications (2)

Publication Number Publication Date
EA200602196A1 true EA200602196A1 (ru) 2007-06-29
EA012431B1 EA012431B1 (ru) 2009-10-30

Family

ID=35335786

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200602196A EA012431B1 (ru) 2004-06-04 2005-05-31 Производные пиразола, фармацевтические композиции и их применение

Country Status (34)

Country Link
US (2) US7598285B2 (ru)
EP (1) EP1756064B1 (ru)
JP (2) JP4108739B2 (ru)
CN (1) CN1964947A (ru)
AR (2) AR049291A1 (ru)
AT (1) ATE395338T1 (ru)
AU (2) AU2005252183B2 (ru)
BR (1) BRPI0511703B8 (ru)
CA (1) CA2566945C (ru)
CR (1) CR8766A (ru)
CY (1) CY1108544T1 (ru)
DE (1) DE602005006806D1 (ru)
DK (1) DK1756064T3 (ru)
EA (1) EA012431B1 (ru)
EC (1) ECSP067062A (ru)
ES (1) ES2306165T3 (ru)
GE (1) GEP20094605B (ru)
HR (1) HRP20080311T3 (ru)
IL (1) IL179754A (ru)
MA (1) MA28673B1 (ru)
MX (1) MXPA06014084A (ru)
MY (1) MY143599A (ru)
NI (1) NI200600290A (ru)
NO (1) NO339149B1 (ru)
NZ (1) NZ551405A (ru)
PE (1) PE20060427A1 (ru)
PL (1) PL1756064T3 (ru)
PT (1) PT1756064E (ru)
SI (1) SI1756064T1 (ru)
TN (1) TNSN06397A1 (ru)
TW (1) TWI293952B (ru)
UA (1) UA85884C2 (ru)
WO (1) WO2005121097A2 (ru)
ZA (1) ZA200609489B (ru)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004210127B2 (en) 2003-01-27 2009-10-01 Merck Sharp & Dohme Corp. Substituted pyrazoles, compositions containing such compounds and methods of use
ES2306165T3 (es) 2004-06-04 2008-11-01 MERCK & CO., INC. Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso.
US7625938B2 (en) 2004-07-22 2009-12-01 Merck & Co., Inc. Substituted pyrazoles, compositions containing such compounds and methods of use
JP2009502923A (ja) 2005-07-26 2009-01-29 メルク エンド カムパニー インコーポレーテッド 置換ピラゾールを合成するための方法
AR056574A1 (es) * 2005-10-19 2007-10-10 Merck & Co Inc Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso
EP2114891A1 (en) * 2007-01-17 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. Substituted pyrazoline compounds with acat inhibition activity
KR20170085615A (ko) 2007-02-09 2017-07-24 메타베이시스 테라퓨틱스, 인크. 글루카곤 수용체의 길항제
WO2009005675A1 (en) * 2007-06-28 2009-01-08 Abbott Laboratories Novel triazolopyridazines
US8232413B2 (en) * 2007-09-12 2012-07-31 Merck Sharp & Dohme Corp. Process for the production of a crystalline glucagon receptor antagonist compound
CN102015641B (zh) 2008-03-05 2014-01-01 武田药品工业株式会社 杂环化合物
EP2251038B1 (en) 2008-03-11 2017-05-10 ASKA Pharmaceutical Co., Ltd. Solid dispersion, pharmaceutical compositions containing the same, and processes for the production of both
US8623818B2 (en) 2008-05-16 2014-01-07 Merck Sharp & Dohme Corp. Glucagon receptor antagonists, compositions, and methods for their use
EP3153501B1 (en) 2008-08-13 2018-11-28 Metabasis Therapeutics, Inc. Glucagon antagonists
RU2008135294A (ru) * 2008-08-29 2010-03-10 Дик Корпорейшн (Jp) Нафталиновые производные
WO2010030722A1 (en) * 2008-09-15 2010-03-18 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
US8361959B2 (en) * 2008-10-03 2013-01-29 Merck Sharp & Dohme Corp. Spiro-imidazolone derivatives as glucagon receptor antagonists
US8324384B2 (en) 2009-02-12 2012-12-04 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2010098994A1 (en) 2009-02-25 2010-09-02 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
US8470773B2 (en) 2009-06-12 2013-06-25 Merck Sharp & Dohme Corp. Thiophenes as glucagon receptor antagonists, compositions, and methods for their use
EP2480077B1 (en) 2009-09-22 2015-02-18 Merck Sharp & Dohme Corp. Pyrrolidines as glucagon receptor antagonists, compositions, and methods for their use
BR112013016033A2 (pt) 2010-12-23 2018-06-05 Pfizer moduladores do receptor de glucagon
EA023517B1 (ru) 2011-02-08 2016-06-30 Пфайзер Инк. Модуляторы глюкагонового рецептора
BR112014000288A2 (pt) 2011-07-22 2017-01-10 Pfizer moduladores do receptor de glucagon de quinolinila
TW201427658A (zh) 2012-12-10 2014-07-16 Merck Sharp & Dohme 藉由投予升糖素受體拮抗劑及膽固醇吸收抑制劑治療糖尿病之方法
US9649294B2 (en) 2013-11-04 2017-05-16 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
CN103933032B (zh) * 2013-12-30 2019-08-23 北京赛林泰医药技术有限公司 作为抗癌药物的吡唑类衍生物的使用方法和用途
US10076504B2 (en) 2014-06-12 2018-09-18 Ligand Pharmaceuticals, Inc. Glucagon antagonists
CN109922831A (zh) 2016-08-30 2019-06-21 瑞泽恩制药公司 通过干扰胰高血糖素受体的信号传导治疗重度胰岛素抵抗的方法
TWI763705B (zh) * 2016-09-06 2022-05-11 比利時商健生藥品公司 可作為升糖素受體拮抗劑之吲哚衍生物
WO2018075792A1 (en) 2016-10-20 2018-04-26 Regeneron Pharmaceuticals, Inc. Methods of lowering blood glucose levels
JP2020531532A (ja) 2017-08-22 2020-11-05 リジェネロン・ファーマシューティカルズ・インコーポレイテッド グルカゴン受容体シグナル伝達に干渉することによって尿素サイクル異常症を治療する方法
CN111954560A (zh) 2018-02-13 2020-11-17 配体药物公司 胰高血糖素受体拮抗剂

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9303993D0 (en) 1993-02-26 1993-04-14 Fujisawa Pharmaceutical Co New heterocyclic derivatives
EP0859771A4 (en) 1995-10-31 2000-03-15 Merck & Co Inc SUBSTITUTED PYRIDYL PYRROLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHOD OF USE
AR008789A1 (es) 1996-07-31 2000-02-23 Bayer Corp Piridinas y bifenilos substituidos
US5776954A (en) 1996-10-30 1998-07-07 Merck & Co., Inc. Substituted pyridyl pyrroles, compositions containing such compounds and methods of use
JP2000514088A (ja) 1996-11-20 2000-10-24 メルク エンド カンパニー インコーポレーテッド グルカゴンアンタゴニストとしてのトリアリール置換イミダゾール
CA2271963A1 (en) 1996-11-20 1998-05-28 Linda L. Chang Triaryl substituted imidazoles, compositions containing such compounds and methods of use
EP0959885A4 (en) 1996-11-20 2002-07-17 Merck & Co Inc TRIARYL SUBSTITUTED IMIDAZOLES AND METHODS OF USE
EP0945438B1 (en) 1996-12-12 2003-03-05 Banyu Pharmaceutical Co., Ltd. Pyrazole derivatives
EP0979077A1 (en) 1997-04-18 2000-02-16 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors in the prevention of cardiovascular disorders
US6613942B1 (en) 1997-07-01 2003-09-02 Novo Nordisk A/S Glucagon antagonists/inverse agonists
US6420427B1 (en) 1997-10-09 2002-07-16 Ono Pharmaceutical Co., Ltd. Aminobutyric acid derivatives
KR20010033241A (ko) 1997-12-19 2001-04-25 스티븐 엠. 오드레 치환된 피리딘 및 피리다진 화합물과 그것의 제약학적 용도
BR9913833A (pt) 1998-09-17 2001-05-29 Bristol Myers Squibb Co Método para tratar diabetes, empregando em inibidor de ap2 e combinação
US6503949B1 (en) 1999-05-17 2003-01-07 Noro Nordisk A/S Glucagon antagonists/inverse agonists
PL364750A1 (en) 1999-08-10 2004-12-13 Nihon Bayer Agrochem K.K. Herbicidal tetrazolinone derivatives
HUP0203165A3 (en) * 1999-11-10 2004-03-29 Takeda Pharmaceutical 5-membered n-heterocyclic compounds with hypoglycemic and hypolipidemic activity
US6562807B2 (en) 2000-06-23 2003-05-13 Novo Nordisk A/S Glucagon antagonists/inverse agonists
AU2001277056B2 (en) * 2000-07-25 2005-09-29 Merck & Co., Inc. N-substituted indoles useful in the treatment of diabetes
WO2002040444A1 (en) 2000-11-17 2002-05-23 Novo Nordisk A/S Glucagon antagonists/inverse agonists
US20030203946A1 (en) 2000-11-17 2003-10-30 Carsten Behrens Glucagon antagonists/inverse agonists
ITMI20010733A1 (it) 2001-04-05 2002-10-05 Recordati Chem Pharm Uso di inibitori dell'isoenzina cox-2 per il trattamento dell'incontinenza urinaria
US6881746B2 (en) 2001-12-03 2005-04-19 Novo Nordick A/S Glucagon antagonists/inverse agonists
US6762318B2 (en) 2001-12-03 2004-07-13 Novo Nordisk A/S Glucagon antagonists
WO2003051357A1 (en) 2001-12-19 2003-06-26 Novo Nordisk A/S Glucagon receptor antagonists/inverse agonists
WO2003053938A1 (en) 2001-12-20 2003-07-03 Novo Nordisk A/S Benzimidazols and indols as glucagon receptor antagonists/inverse agonisten
CA2473591C (en) 2002-02-01 2011-11-01 Dainippon Pharmaceutical Co., Ltd. 2-furancarboxylic acid hydrazides and pharmaceutical compositions containing the same
ATE505223T1 (de) 2002-07-19 2011-04-15 Baxter Int System für die peritonealdialyse
EP1400243A1 (en) 2002-09-19 2004-03-24 Tanabe Seiyaku Co., Ltd. Calcium-activated K channel activator
JP2006509015A (ja) * 2002-12-04 2006-03-16 メルク　エンド　カムパニー　インコーポレーテッド スピロ環尿素、そのような化合物を含有する組成物、及び使用方法
AU2004210127B2 (en) * 2003-01-27 2009-10-01 Merck Sharp & Dohme Corp. Substituted pyrazoles, compositions containing such compounds and methods of use
US20040248937A1 (en) * 2003-04-14 2004-12-09 The Institute For Pharmaceutical Discovery Llc Substituted phenylalkanoic acids for the treatment of diabetes
AU2004238240A1 (en) * 2003-05-09 2004-11-25 Merck & Co., Inc. Benzimidazoles, compositions containing such compounds and methods of use
ES2306165T3 (es) * 2004-06-04 2008-11-01 MERCK & CO., INC. Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso.
US7625938B2 (en) * 2004-07-22 2009-12-01 Merck & Co., Inc. Substituted pyrazoles, compositions containing such compounds and methods of use
AR056574A1 (es) * 2005-10-19 2007-10-10 Merck & Co Inc Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso

Also Published As

Publication number Publication date
BRPI0511703B1 (pt) 2018-07-17
PL1756064T3 (pl) 2008-11-28
PE20060427A1 (es) 2006-06-19
TWI293952B (en) 2008-03-01
AU2008229701C1 (en) 2010-07-29
ES2306165T3 (es) 2008-11-01
EP1756064B1 (en) 2008-05-14
JP2008505062A (ja) 2008-02-21
NZ551405A (en) 2009-06-26
ATE395338T1 (de) 2008-05-15
AU2008229701A1 (en) 2008-10-30
TNSN06397A1 (en) 2008-02-22
PT1756064E (pt) 2008-07-22
CA2566945C (en) 2010-09-21
CY1108544T1 (el) 2014-04-09
JP4733153B2 (ja) 2011-07-27
US7799818B2 (en) 2010-09-21
US20090176854A1 (en) 2009-07-09
AU2005252183A1 (en) 2005-12-22
NO339149B1 (no) 2016-11-14
SI1756064T1 (sl) 2008-12-31
CR8766A (es) 2007-08-28
CA2566945A1 (en) 2005-12-22
NO20070073L (no) 2007-03-05
MY143599A (en) 2011-06-15
WO2005121097A2 (en) 2005-12-22
EA012431B1 (ru) 2009-10-30
IL179754A (en) 2013-12-31
US7598285B2 (en) 2009-10-06
NI200600290A (es) 2007-08-07
UA85884C2 (ru) 2009-03-10
JP4108739B2 (ja) 2008-06-25
DE602005006806D1 (de) 2008-06-26
GEP20094605B (en) 2009-02-10
AU2005252183B2 (en) 2008-07-17
AR088919A2 (es) 2014-07-16
AU2008229701B2 (en) 2010-03-04
BRPI0511703A (pt) 2008-01-08
MA28673B1 (fr) 2007-06-01
BRPI0511703B8 (pt) 2021-05-25
ZA200609489B (en) 2007-10-31
CN1964947A (zh) 2007-05-16
DK1756064T3 (da) 2008-09-22
MXPA06014084A (es) 2007-02-15
HRP20080311T3 (en) 2008-07-31
AR049291A1 (es) 2006-07-12
WO2005121097A3 (en) 2006-02-16
JP2008150388A (ja) 2008-07-03
EP1756064A2 (en) 2007-02-28
TW200604179A (en) 2006-02-01
US20050272794A1 (en) 2005-12-08
IL179754A0 (en) 2007-05-15
ECSP067062A (es) 2007-01-26

Similar Documents

Publication Publication Date Title
EA200602196A1 (ru) Производные пиразола, композиции, содержащие эти соединения, и способы применения
BR0313176A (pt) Composições de pirazol úteis como inibidores de gsk-3
DE602005017895D1 (de) Pyrazolamid-derivate, diese verbindungen enthaltende zusammensetzungen und anwendungsverfahren
TW200745044A (en) Pyrazole derivatives, compositions containing such compounds and methods of use
EA200601555A1 (ru) Замещенные индазол-о-глюкозиды
IS7965A (is) Þíenópýrimidíndíón og notkun þeirra í breytingu ásjálfsnæmissjúkdómi
EA200601554A1 (ru) Замещенные индол-о-глюкозиды
NO20053470L (no) Triazolopyridaziner som proteinkinase-inhibitorer
ATE433447T1 (de) Pyrimiidinverbindungen
WO2006086562A3 (en) Phenylazetidinone derivatives
NO20055516L (no) Kannabinoidreceptorligander og anvendelser derav
EA200701930A1 (ru) Производные пиримидина для лечения гиперпролиферативных нарушений
NO20064325L (no) Heteroarylaminopyrazolderivativer nyttige for behandling av diabetes
EA200801565A1 (ru) Производные пиримидиниларилмочевины в качестве ингибиторов фактора роста фибробластов ( fgf-фактора )
ATE532781T1 (de) 5-(acylamino)indazol-derivate als kinase- inhibitoren
MA27880A1 (fr) Derives de tetrahydrocarbazole et leur utilisation pharmaceutique
MX2009007337A (es) Indazoles sustituidos con 5-piridinona.
DE502004002571D1 (de) Substituierte 3-pyrrolidin-indol-derivate
SE0302139D0 (sv) Novel compounds
ATE482955T1 (de) Azabicyclooctan-3-onderivate und deren verwendung
SE0402925D0 (sv) Novel Compounds
TR200100895T2 (tr) Heterosiklik ikameli propanolamin türevleri, üretimi, ilaçları,kullanımı
DE60112742D1 (de) Verwendung von pyrazolderivaten zur behandlung von unfruchtbarkeit
NO20054346L (no) Sammensetninger og fremgangsmater for forebygging og behandling av endotoksinrelaterte sykdommer og tilstander
EA200600992A1 (ru) Амиды тиазолидинона, амиды тиазолидинкарбоновой кислоты, способы их получения и их применение

Legal Events

Date Code Title Description
PD4A Registration of transfer of a eurasian patent in accordance with the succession in title
PD4A Registration of transfer of a eurasian patent in accordance with the succession in title
TC4A Change in name of a patent proprietor in a eurasian patent
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU